Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as bispecific
MCLA-145 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| MCLA-145 | EXPERIMENTAL | In Part 1, the dose escalation phase, patients with advanced or recurrent/metastatic solid tumors or B-cell lymphomas will receive escalating doses of MCLA-145 (either Q2W for those patients in treatment at the time of Amendment #4 or Q3W with Amendment #4 approval). Treatment will be with MCLA-145 (monotherapy) for Group A, or in combination with pembrolizumab for Group B, until MTD or RDE is reached. In Part 2, the expansion phase, participants with advanced or metastatic solid tumors will receive intravenous infusion of MCLA-145 either in monotherapy (Group A) or in combination with pembrolizumab (Group B) at the recommended phase II dose every 3 weeks. The duration of each treatment cycle is 21 days |
| Group B Combination Treatment | EXPERIMENTAL | Patients in Group B will be treated with MCLA-145 in Combination with pembrolizumab 200mg Q3W. |
| Name | Type | Description |
|---|---|---|
| MCLA-145 | DRUG | full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137 |
| Pembrolizumab (Keytruda) | DRUG | Group B patients will be treated in combination with MCLA-145 and pembrolizumab 200mg Q3W. |
Inclusion Criteria: * Histologically or cytologically confirmed advanced or recurrent/metastatic solid tumors or B-cell lymphomas, that are considered non-amenable to surgery or other curative treatments or procedures (if applicable) * Measureable disease per RECIST v1.1 or Lugano Criteria * Easter...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
MCLA-145 is an investigational therapy being studied for the treatment of advanced cancer, including advanced or metastatic solid tumors and adult B-cell lymphoma. It is being developed by Merus N.V. and has been evaluated in a Phase 1 clinical trial in patients with these malignancies.
MCLA-145 targets CD137 and PD-L1. CD137 is a costimulatory receptor on immune cells, and PD-L1 is an immune checkpoint protein. By binding both targets, MCLA-145 is designed to activate anti-tumor immune responses while blocking PD-L1-mediated immune suppression.
MCLA-145 is being developed by Merus N.V., a clinical-stage oncology company. Merus N.V. trades on the Nasdaq under the ticker symbol MRUS.
MCLA-145 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The Phase 1 trial has been completed.
MCLA-145 has been studied in a Phase 1 clinical trial, NCT03922204, titled "A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies." The trial enrolled 72 patients across the United States, Belgium, Netherlands, and Spain and is now completed.